<DOC>
	<DOCNO>NCT01029652</DOCNO>
	<brief_summary>The purpose 12-week core study demonstrate canakinumab give upon acute gout flare relieve sign symptom prevents recurrence gout flare patient frequent flare gout non-steroidal anti-inflammatory drug ( NSAIDs ) and/ colchicine contraindicate , tolerate , ineffective . The efficacy canakinumab compare corticosteroid triamcinolone acetonide . The purpose first 12-week extension study collect additional safety , tolerability efficacy data patient complete core study CACZ885H2356 . The purpose second 48 week open-label extension study collect additional long-term safety tolerability data patient complete first extension study CACZ885H2356E1 .</brief_summary>
	<brief_title>Canakinumab Treatment Acute Gout Flares Prevention New Flares Patients Unable Use Non-steroidal Anti-inflammatory Drugs ( NSAIDs ) and/or Colchicine Including 12 Weeks Extension Open-label 48 Weeks Extension Study</brief_title>
	<detailed_description>Masking : Core : Double Blind ( Subject , Investigator ) Extension 1 : Double Blind ( Subject , Investigator ) Extension 2 : Open-label , terminate</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Core Study : Inclusion criterion : Meeting American College Rheumatology ( ACR ) 1977 preliminary criterion classification acute arthritis primary gout Onset current acute gout flare within 5 day prior study entry Baseline pain intensity ≥ 50 mm 0100 mm visual analog scale ( VAS ) History ≥ 3 gout flare within 12 month prior study entry Contraindication , intolerance , lack efficacy nonsteroidal antiinflammatory drug ( NSAIDs ) and/or colchicine Exclusion criterion : Rheumatoid arthritis , evidence/suspicion infectious/septic arthritis , acute inflammatory arthritis Presence severe renal function impairment Use specify pain relief medication biologics ( corticosteroid , narcotic , paracetamol/acetominophen , ibuprofen , colchicine , ILblocker , tumor necrosis factor inhibitor ) within specify period prior study entry Live vaccination within 3 month prior randomization Requirement administration antibiotic latent tuberculosis ( TB ) Refractory heart failure ( Stage D ) Unstable cardiac arrhythmia unstable symptomatic coronary ischemia Any active recurrent bacterial , fungal , viral infection Extension Study 1 : Inclusion Completion Core study . A patient define complete core study complete study include visit 7 . Exclusion Continuation extension study consider inappropriate treating physician . Extension Study 2 : Inclusion Completed first extension study CACZ885H2356E1 . A patient define complete first extension study complete study include Visit 10 ) . Exclusion Continuation extension study consider inappropriate treating physician Other protocoldefined inclusionexclusion criterion apply core extension study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>frequent flare</keyword>
	<keyword>gout</keyword>
	<keyword>anti-interleukin-1β monoclonal antibody</keyword>
</DOC>